Deerfield Management LRMR Position
Active5-Fund ConvergenceDeerfield Management held their position in Larimar Therapeutics, Inc. (LRMR) in Q4 2025, holding $116.6M worth of shares across 30,606,974 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
LRMR is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for CTI-1601 in 290 days (Jan 31, 2027), making the timing of Deerfield's position particularly relevant.
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Full company profile →Short Interest
9.7%
0.7 days to cover
Deerfield Management LRMR Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Held | 30,606,974 | — | $116.6M |
| Q3 2025 | Increased | 30,606,974 | +9,375,000 | $98.9M |
| Q2 2025 | Held | 21,231,974 | — | $61.4M |
| Q1 2025 | Held | 21,231,974 | — | $45.6M |
| Q4 2024 | Held | 21,231,974 | — | $82.2M |
| Q3 2024 | Held | 21,231,974 | — | $139.1M |
| Q2 2024 | Held | 21,231,974 | — | $153.9M |
| Q1 2024 | Increased | 21,231,974 | +4,290,617 | $161.2M |
| Q4 2023 | Held | 16,941,357 | — | $77.1M |
| Q3 2023 | Held | 16,941,357 | — | $66.9M |
| Q2 2023 | Held | 16,941,357 | — | $53.0M |
| Q1 2023 | New | 16,941,357 | +16,941,357 | $76.7M |
Frequently Asked Questions
Does Deerfield Management own LRMR?
Yes. As of Q4 2025, Deerfield Management holds 30,606,974 shares of Larimar Therapeutics, Inc. (LRMR) valued at $116.6M. This data comes from their SEC 13F filing.
How many hedge funds own LRMR?
5 specialist biotech hedge funds currently hold LRMR, including RA Capital Management, RTW Investments, Perceptive Advisors and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy LRMR?
Deerfield Management's position in LRMR was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's LRMR position increasing or decreasing?
Deerfield Management held their LRMR position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
LRMRCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →